Thursday, November 12, 2026||
MultiKhabarMultiKhabar

Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity

FO
Forbes Business
By Bruce Y. Lee, Senior Contributor
Share:WhatsAppFacebookX (Twitter)Telegram
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity
Photo / Coverage: Forbes BusinessCredit: Bruce Y. Lee, Senior Contributor
EXECUTIVE SUMMARY

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand

Key Takeaways

  • Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity.

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand

Share:WhatsAppFacebookX (Twitter)Telegram

Read Complete Original Article

Published originally on Forbes Business

Visit Publisher Site →

Related News

🇺🇸 United States
Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!

Get it on Google Play